Anna Molotkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Molotkova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Aykut Üren
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
28 shared publications - Emre Deniz
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
28 shared publications - Jeffrey A. Toretsky
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
28 shared publications - Purushottam Babu Tiwari
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
28 shared publications - Adam Shlien
Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
25 shared publications - Dusan Pesic
SickKids 3 Department of Paediatric Laboratory Medicine Toronto, Canada
25 shared publications
Latest Publications
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 7 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Modulation of ROME expression affects many different pathways in human cancer cells.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 7 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Modulation of ROME expression affects many different pathways in human cancer cells.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Rome knockdown significantly affects calcium signaling and developmental pathways in zebrafish embryos. A, Uniform Manifold Approximation and Projection (UMAP) of 49 annotated clusters from single cells isolated from control MO–injected zebrafish embryos and rome MO–injected zebrafish embryos at 48 hpf. B, Volcano plot showing differentially expressed genes upon rome knockdown by morpholino across all cell populations (pseudobulk). FC, fold change. C and D, Significantly enriched pathways among upregulated genes (C) and downregulated genes (D) from pseudo-bulk differential expression analysis (top 20 pathways, adjusted P value < 0.05). GO, gene ontology. E–H, Violin plots showing significantly increased icn (E), s100t (F), rspo1 (G), and ctslb (H) expression in zebrafish embryos injected with the rome MO compared with that in embryos injected with the control MO. All comparisons shown have an adjusted P value < 0.05 and an average log2 fold change > 0.66 or < −0.66 (denoted by an asterisk: *). I, Treatment with Wnt pathway inhibitor, ICG-001, rescued developmental defects in zebrafish embryos with rome knockdown at 24 hpf and 48 hpf (DMSO group: n = 43; ICG-001 treatment group: n = 41). Statistical significance was calculated via the Fisher exact test (two-sided).
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Rome knockdown significantly affects calcium signaling and developmental pathways in zebrafish embryos. A, Uniform Manifold Approximation and Projection (UMAP) of 49 annotated clusters from single cells isolated from control MO–injected zebrafish embryos and rome MO–injected zebrafish embryos at 48 hpf. B, Volcano plot showing differentially expressed genes upon rome knockdown by morpholino across all cell populations (pseudobulk). FC, fold change. C and D, Significantly enriched pathways among upregulated genes (C) and downregulated genes (D) from pseudo-bulk differential expression analysis (top 20 pathways, adjusted P value < 0.05). GO, gene ontology. E–H, Violin plots showing significantly increased icn (E), s100t (F), rspo1 (G), and ctslb (H) expression in zebrafish embryos injected with the rome MO compared with that in embryos injected with the control MO. All comparisons shown have an adjusted P value < 0.05 and an average log2 fold change > 0.66 or < −0.66 (denoted by an asterisk: *). I, Treatment with Wnt pathway inhibitor, ICG-001, rescued developmental defects in zebrafish embryos with rome knockdown at 24 hpf and 48 hpf (DMSO group: n = 43; ICG-001 treatment group: n = 41). Statistical significance was calculated via the Fisher exact test (two-sided).
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a 153–amino acid transmembrane glycoprotein. A, Western blots of TC-71 lysates transfected with EV or ROME-HA for 24 hours blotted with the commercially available anti-HA antibody, ICD-6 (monoclonal antibody against the predicted ICD of ROME), and ECD-5 (monoclonal antibody against the predicted ECD of ROME) are shown. B, ROME was knocked out via CRISPR/Cas9 in TC-71 cells. Successful knockout was confirmed by immunoprecipitation and Western blotting with a ROME monoclonal antibody (ICD-6). C, Coomassie blue staining was used to verify the purity of recombinant ROME-FL and ECD proteins and the synthetic ICD peptide. Western blotting with ROME ICD-6 and ECD-5 monoclonal antibodies was performed to confirm protein identities. D, SPR sensorgrams demonstrating the binding of the anti-ROME monoclonal antibody ICD-6 to the ROME ICD and FL proteins and the binding of the anti-ROME monoclonal antibody ECD-5 to the ROME ECD and FL proteins. The antibodies were injected in duplicate at 200, 100, 50, 25, 12.5, and 6.25 nmol/L. The red lines are the actual data and the black lines indicate the curve fit. E, Three-dimensional structure of ROME predicted by AlphaFold. F, A diagram of the ROME amino acid sequence with three predicted domains is shown. Circles correspond to phosphorylation sites and triangles correspond to glycosylation sites. The black color designates sites predicted in silico and the blue color designates sites confirmed by MS. G, Homology between human, mouse, and zebrafish ROME proteins is shown. The Drosophila inaF motif (from the INAF-D protein) is shown for comparison. The black line box indicates the transmembrane domain. Asterisks (*) indicate identical amino acids (aa) and colons (:) indicate amino acids with similarity among all three species. H, Phylogenetic tree showing the high evolutionary conservation of the ROME protein in vertebrates. I, Compared with the eGFP control, ROME-GFP localizes to the plasma membrane of TC-71 cells (quantification shown in the graph to the right). J, ROME-HA was expressed in TC-71 cells and detected primarily in the membrane fraction, as well as the soluble nuclear fraction. α-Tubulin was used as a cytoplasmic fraction control, CD99 was used as a membrane fraction control, and lamin A/C was used as a soluble nuclear fraction control. K, Lysates from TC-71 cells transfected with EV or ROME-FLAG were treated with a deglycosylase mixture. Western blotting with anti-FLAG antibody was performed to detect ROME-FLAG.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a 153–amino acid transmembrane glycoprotein. A, Western blots of TC-71 lysates transfected with EV or ROME-HA for 24 hours blotted with the commercially available anti-HA antibody, ICD-6 (monoclonal antibody against the predicted ICD of ROME), and ECD-5 (monoclonal antibody against the predicted ECD of ROME) are shown. B, ROME was knocked out via CRISPR/Cas9 in TC-71 cells. Successful knockout was confirmed by immunoprecipitation and Western blotting with a ROME monoclonal antibody (ICD-6). C, Coomassie blue staining was used to verify the purity of recombinant ROME-FL and ECD proteins and the synthetic ICD peptide. Western blotting with ROME ICD-6 and ECD-5 monoclonal antibodies was performed to confirm protein identities. D, SPR sensorgrams demonstrating the binding of the anti-ROME monoclonal antibody ICD-6 to the ROME ICD and FL proteins and the binding of the anti-ROME monoclonal antibody ECD-5 to the ROME ECD and FL proteins. The antibodies were injected in duplicate at 200, 100, 50, 25, 12.5, and 6.25 nmol/L. The red lines are the actual data and the black lines indicate the curve fit. E, Three-dimensional structure of ROME predicted by AlphaFold. F, A diagram of the ROME amino acid sequence with three predicted domains is shown. Circles correspond to phosphorylation sites and triangles correspond to glycosylation sites. The black color designates sites predicted in silico and the blue color designates sites confirmed by MS. G, Homology between human, mouse, and zebrafish ROME proteins is shown. The Drosophila inaF motif (from the INAF-D protein) is shown for comparison. The black line box indicates the transmembrane domain. Asterisks (*) indicate identical amino acids (aa) and colons (:) indicate amino acids with similarity among all three species. H, Phylogenetic tree showing the high evolutionary conservation of the ROME protein in vertebrates. I, Compared with the eGFP control, ROME-GFP localizes to the plasma membrane of TC-71 cells (quantification shown in the graph to the right). J, ROME-HA was expressed in TC-71 cells and detected primarily in the membrane fraction, as well as the soluble nuclear fraction. α-Tubulin was used as a cytoplasmic fraction control, CD99 was used as a membrane fraction control, and lamin A/C was used as a soluble nuclear fraction control. K, Lysates from TC-71 cells transfected with EV or ROME-FLAG were treated with a deglycosylase mixture. Western blotting with anti-FLAG antibody was performed to detect ROME-FLAG.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
CRISPR/Cas9 library sequencing primers.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
CRISPR/Cas9 library sequencing primers.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
List of gRNAs identified in CRISPR/Cas9 transcriptional activation screen
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
List of gRNAs identified in CRISPR/Cas9 transcriptional activation screen
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a highly conserved, phosphorylated transmembrane protein that is also present in the nucleus.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 2 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME is a highly conserved, phosphorylated transmembrane protein that is also present in the nucleus.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 8 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME expression drives metastasis development in vivo. A, Timeline of tail vein metastasis experiments. B, In a tail vein metastasis model, mice injected with ROME-overexpressing TC-71 cells (n = 11) had a higher total mass of metastatic nodules than did controls (n = 10). C, In a tail vein metastasis model, mice injected with ROME-KO TC-71 cells (n = 11) had a lower total mass of metastases than controls injected with WT TC71 cells (n = 11). Statistical significance was determined via an unpaired t test (one-tailed) for B and C. D, Diagram of the orthotopic Ewing sarcoma leg amputation experimental timeline. E, Representative gross images of lungs from mice injected with TC-71 cells overexpressing ROME or with EV (left) with quantification (middle). Representative images of H&E staining are shown on the right confirming metastatic nodules in the lungs of SCID mice. Statistical significance was calculated by the Fisher exact test (one-sided). F, TC-71 ROME-KO cells displayed significantly reduced primary tumor recurrence [n = 10 per group, log-rank (Mantel–Cox) test]. G, ROME is expressed throughout many different tumor types (CNS, central nervous system; HEPAC, hepatocellular carcinoma and cholangioma; KICH, kidney chromophobe and other renal carcinoma; KIPCC, papillary cell renal carcinoma; OV, ovarian cystadenocarcinoma; PAAD, pancreatic ductal adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; SCC/BLCA, squamous cell or bladder carcinoma; TGCT SEM, testicular germ cell tumor, seminoma). H, Kaplan–Meier curves of patient survival stratified by high (red line) and low (black line) ROME expression (from the Kaplan–Meier plotter database). [A and D, Created in BioRender. Lab, S. (2026) https://BioRender.com/atgnfw0.]
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 8 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME expression drives metastasis development in vivo. A, Timeline of tail vein metastasis experiments. B, In a tail vein metastasis model, mice injected with ROME-overexpressing TC-71 cells (n = 11) had a higher total mass of metastatic nodules than did controls (n = 10). C, In a tail vein metastasis model, mice injected with ROME-KO TC-71 cells (n = 11) had a lower total mass of metastases than controls injected with WT TC71 cells (n = 11). Statistical significance was determined via an unpaired t test (one-tailed) for B and C. D, Diagram of the orthotopic Ewing sarcoma leg amputation experimental timeline. E, Representative gross images of lungs from mice injected with TC-71 cells overexpressing ROME or with EV (left) with quantification (middle). Representative images of H&E staining are shown on the right confirming metastatic nodules in the lungs of SCID mice. Statistical significance was calculated by the Fisher exact test (one-sided). F, TC-71 ROME-KO cells displayed significantly reduced primary tumor recurrence [n = 10 per group, log-rank (Mantel–Cox) test]. G, ROME is expressed throughout many different tumor types (CNS, central nervous system; HEPAC, hepatocellular carcinoma and cholangioma; KICH, kidney chromophobe and other renal carcinoma; KIPCC, papillary cell renal carcinoma; OV, ovarian cystadenocarcinoma; PAAD, pancreatic ductal adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; SCC/BLCA, squamous cell or bladder carcinoma; TGCT SEM, testicular germ cell tumor, seminoma). H, Kaplan–Meier curves of patient survival stratified by high (red line) and low (black line) ROME expression (from the Kaplan–Meier plotter database). [A and D, Created in BioRender. Lab, S. (2026) https://BioRender.com/atgnfw0.]
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 6 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Supplementary data for single cell RNA sequencing experiment
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 6 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
Supplementary data for single cell RNA sequencing experiment
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME protein negatively regulates the Wnt pathway and calcium signaling in human cancer cells. A and B, Compared with EV control cells, TC-71 (A) and TC-32 (B) cells stably overexpressing ROME were less responsive to recombinant human Wnt3a protein as measured by TOPFlash β-catenin–responsive luciferase reporter. C, TC-71 cells with ROME knockdown by siRNA were more responsive to Wnt3a. D, Endogenous Wnt pathway activity in the colorectal cancer cell line HCT116 was significantly decreased by ROME expression (Western blots confirming ROME-HA expression on the right). Statistical significance was calculated by an unpaired t test (two-tailed) for A–D. E, ROME co-immunoprecipitates with β-catenin in β-catenin pulldown experiments. F, β-Catenin co-immunoprecipitates with ROME in ROME pulldown experiments. G, SPR sensorgrams showing direct binding between the recombinant full-length ROME protein and β-catenin protein. β-Catenin was immobilized on the surface and full-length ROME protein was injected in duplicate at concentrations of 1,250, 416.7, 138.9, 46.3, 15.4, and 5.12 nmol/L. The red lines are the actual data, and the black lines indicate the curve fit. H, ROME expression decreases β-catenin and TCF4 interaction (measured by co-IP). I–K, The Ca2+ response was decreased in A4573, STA-ET-7.2, and TC-71 cells overexpressing ROME compared with that in EV-transfected cells when the cells were stimulated with ATP or FBS after overnight serum starvation. L, The Ca2+ response was greater in the TC-71 cells with ROME KO than in the WT cells. Statistical significance was calculated by an unpaired t test (two-tailed) for I–L.
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME protein negatively regulates the Wnt pathway and calcium signaling in human cancer cells. A and B, Compared with EV control cells, TC-71 (A) and TC-32 (B) cells stably overexpressing ROME were less responsive to recombinant human Wnt3a protein as measured by TOPFlash β-catenin–responsive luciferase reporter. C, TC-71 cells with ROME knockdown by siRNA were more responsive to Wnt3a. D, Endogenous Wnt pathway activity in the colorectal cancer cell line HCT116 was significantly decreased by ROME expression (Western blots confirming ROME-HA expression on the right). Statistical significance was calculated by an unpaired t test (two-tailed) for A–D. E, ROME co-immunoprecipitates with β-catenin in β-catenin pulldown experiments. F, β-Catenin co-immunoprecipitates with ROME in ROME pulldown experiments. G, SPR sensorgrams showing direct binding between the recombinant full-length ROME protein and β-catenin protein. β-Catenin was immobilized on the surface and full-length ROME protein was injected in duplicate at concentrations of 1,250, 416.7, 138.9, 46.3, 15.4, and 5.12 nmol/L. The red lines are the actual data, and the black lines indicate the curve fit. H, ROME expression decreases β-catenin and TCF4 interaction (measured by co-IP). I–K, The Ca2+ response was decreased in A4573, STA-ET-7.2, and TC-71 cells overexpressing ROME compared with that in EV-transfected cells when the cells were stimulated with ATP or FBS after overnight serum starvation. L, The Ca2+ response was greater in the TC-71 cells with ROME KO than in the WT cells. Statistical significance was calculated by an unpaired t test (two-tailed) for I–L.
- Open Access
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME expression increases cell motility and chemotaxis in vitro. A, TC-71 cells stably overexpressing ROME demonstrated increased wound closure compared with that of a control cell line, and TC-71 cells with ROME KO by CRISPR/Cas9 demonstrated decreased wound closure compared with that of WT cells in scratch assays. At least two independent experiments were performed, and average wound closure with SEM was quantified. Statistical significance was calculated by an unpaired t test (two-tailed). B–E, Compared with EV control cells, A4573, TC-71, and Hs746.T cells stably expressing ROME presented increased chemotaxis in Boyden chamber assays. F, CHLA-10 cells with ROME KO via CRISPR/Cas9 showed decreased chemotaxis compared with that of WT cells. G–I, ROME KO (TC-71) or knockdown (769-P and Hs746.T) decreased the chemotaxis of cancer cells. J and K, Rescue of ROME expression by an exogenous vector restored chemotaxis in both CHLA-10 and TC-71 cells. At least two independent experiments with three biological replicates were performed for each Boyden chamber assay. Statistical significance was calculated by an unpaired t test (two-tailed).
- 5 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis
ROME expression increases cell motility and chemotaxis in vitro. A, TC-71 cells stably overexpressing ROME demonstrated increased wound closure compared with that of a control cell line, and TC-71 cells with ROME KO by CRISPR/Cas9 demonstrated decreased wound closure compared with that of WT cells in scratch assays. At least two independent experiments were performed, and average wound closure with SEM was quantified. Statistical significance was calculated by an unpaired t test (two-tailed). B–E, Compared with EV control cells, A4573, TC-71, and Hs746.T cells stably expressing ROME presented increased chemotaxis in Boyden chamber assays. F, CHLA-10 cells with ROME KO via CRISPR/Cas9 showed decreased chemotaxis compared with that of WT cells. G–I, ROME KO (TC-71) or knockdown (769-P and Hs746.T) decreased the chemotaxis of cancer cells. J and K, Rescue of ROME expression by an exogenous vector restored chemotaxis in both CHLA-10 and TC-71 cells. At least two independent experiments with three biological replicates were performed for each Boyden chamber assay. Statistical significance was calculated by an unpaired t test (two-tailed).